Brief report: Retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder

Journal of Autism and Developmental Disorders

Volumn 43, Issue 5, 2013, Pages 1243-1247

  Douglas, Jessica F ^a,b   Sanders, Kevin B ^a   Hannah Benneyworth, M ^a,c   Smith, Jessica L ^a   Dejean, Virginia M ^a   McGrew, Susan G ^a   Veenstra Vanderweele, Jeremy ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Centerstone 332 ^*  (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Anticonvulsant; Antiepileptic; Mood stabilizer; Pervasive developmental disorder; Sodium channel

Indexed keywords

OXCARBAZEPINE;

ADOLESCENT; ADULT; AGGRESSION; AGITATION; ANGER; ARTICLE; AUTISM; AUTOMUTILATION; CHILD; CLINICAL ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPONATREMIA; IRRITABILITY; MALE; MEDICAL RECORD; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SCREAMING SYNDROME; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; CARBAMAZEPINE; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; IRRITABLE MOOD; MALE; PSYCHOMOTOR AGITATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877923600     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-012-1661-2     Document Type: Article

References (37)

1. Aman, M. G., Lam, K. S., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33(5), 527-534.
2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders-text revision (DSM-IV-TR) (4th ed.). Washington, D.C.: American Psychiatric Association Press, Inc.
3. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention. (2007). Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR Surveillance Summaries, 56(1), 12-28.
4. Barry, J. J., Lembke, A., & Bullock, K. D. (2004). Current status of the utilization of antiepileptic treatments in mood, anxiety and aggression: Drugs and devices. Clinical EEG and Neuroscience, 35(1), 4-13.
5. Belsito, K., Law, P., Kirk, K., Landa, R., & Zimmerman, A. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31(2), 175-181.
6. Cueva, J. E., Overall, J. E., Small, A. M., Armenteros, J. L., Perry, R., & Campbell, M. (1996). Carbamazepine in aggressive children with conduct disorder: A double-blind and placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 35(4), 480-490. doi: 10.1097/00004583-199604000-00014.
7. Danielsson, S., Gillberg, I. C., Billstedt, E., Gillberg, C., & Olsson, I. (2005). Epilepsy in young adults with autism: A prospective population-based follow-up study of 120 individuals diagnosed in childhood. Epilepsia, 46(6), 918-923. doi: 10.1111/j.1528-1167.2005.57504.x.
8. Di Martino, A., & Tuchman, R. F. (2001). Antiepileptic drugs: Affective use in autism spectrum disorders. Pediatric Neurology, 25(3), 199-207.
9. Gayatri, N. A., & Livingston, J. H. (2006). Aggravation of epilepsy by anti-epileptic drugs. Developmental Medicine and Child Neurology, 48(5), 394-398. doi: 10.1017/S0012162206000843.
10. Gjevik, E., Eldevik, S., Fjaeran-Granum, T., & Sponheim, E. (2011). Kiddie-SADS reveals high rates of DSM-IV disorders in children and adolescents with autism spectrum disorders. Journal of Autism and Developmental Disorders, 41(6), 761-769. doi: 10.1007/s10803-010-1095-7.
11. Grunze, H. C. (2008). The effectiveness of anticonvulsants in psychiatric disorders. Dialogues in Clinical Neuroscience, 10(1), 77-89.
12. Guy, W. (1976). ECDEU assessment manual for psychopharmacology. Rockville, MD: United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
13. Hirschfeld, R. M., & Kasper, S. (2004). A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. International Journal of Neuropsychopharmacology, 7(4), 507-522. doi: 10.1017/S1461145704004651.
14. Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35(4), 990-998. doi: 10.1038/npp.2009.202.
15. Joshi, G., Petty, C., Wozniak, J., Henin, A., Fried, R., Galdo, M., et al. (2010). The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: A large comparative study of a psychiatrically referred population. Journal of Autism and Developmental Disorders, 40(11), 1361-1370. doi: 10.1007/s10803-010-0996-9.
16. Kakkar, A. K., Rehan, H. S., Unni, K. E., Gupta, N. K., Chopra, D., & Kataria, D. (2009). Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: A pilot study. European Psychiatry, 24(3), 178-182. doi: 10.1016/j.eurpsy.2008.12.014.
17. Kapetanovic, S. (2007). Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors. American Journal of Psychiatry, 164(5), 832-833. doi: 10.1176/appi.ajp.164.5.832.
18. Langworthy-Lam, K. S., Aman, M. G., & Van Bourgondien, M. E. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12(4), 311-321. doi: 10.1089/104454602762599853.
19. Levy, S. E., Giarelli, E., Lee, L. C., Schieve, L. A., Kirby, R. S., Cunniff, C., et al. (2010). Autism spectrum disorder and co-occurring developmental, psychiatric, and medical conditions among children in multiple populations of the United States. Journal of Developmental and Behavioral Pediatrics, 31(4), 267-275. doi: 10.1097/DBP.0b013e3181d5d03b.
20. Lopez-Larson, M., & Frazier, J. A. (2006). Empirical evidence for the use of lithium and anticonvulsants in children with psychiatric disorders. Harvard Review of Psychiatry, 14(6), 285-304. doi: 10.1080/10673220601082869.
21. Mandell, D. S. (2008). Psychiatric hospitalization among children with autism spectrum disorders. Journal of Autism and Developmental Disorders, 38(6), 1059-1065. doi: 10.1007/s10803-007-0481-2.
22. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110-1119. doi: 10.1097/CHI.0b013e3181b76658.
23. Matson, J. L., & Nebel-Schwalm, M. S. (2007). Comorbid psychopathology with autism spectrum disorder in children: An overview. Research in Developmental Disabilities, 28(4), 341-352. doi: 10.1016/j.ridd.2005.12.004.
24. McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314-321.
25. McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(5), e1312-e1321. doi: 10.1542/peds.2011-0427.
26. Monji, A., Maekawa, T., Yanagimoto, K., Yoshida, I., & Hashioka, S. (2004). Carbamazepine may trigger new-onset epileptic seizures in an individual with autism spectrum disorders: A case report. European Psychiatry, 19(5), 322-323. doi: 10.1016/j.eurpsy.2004.06.001.
27. Oswald, D. P., & Sonenklar, N. A. (2007). Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 17(3), 348-355. doi: 10.1089/cap.2006.17303.
28. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533-1540. doi: 10.1542/peds.2008-3782.
29. Parikh, M. S., Kolevzon, A., & Hollander, E. (2008). Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability. Journal of Child and Adolescent Psychopharmacology, 18(2), 157-178. doi: 10.1089/cap.2007.0041.
30. Pedrini, M., Noguera, A., Vinent, J., Torra, M., & Jimenez, R. (2009). Acute oxcarbazepine overdose in an autistic boy. British Journal of Clinical Pharmacology, 67(5), 579-581. doi: 10.1111/j.1365-2125.2009.03398.x.
31. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634-e641. doi: 10.1542/peds.2003-0264-F.
32. Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry, 47(8), 921-929. doi: 10.1097/CHI.0b013e318179964f.
33. Stigler, K. A., & McDougle, C. J. (2008). Pharmacotherapy of irritability in pervasive developmental disorders. Child and Adolescent Psychiatric Clinics of North America, 17(4), 739-752, vii-viii. doi: 10.1016/j.chc.2008.06.002.
34. Tuchman, R., & Rapin, I. (2002). Epilepsy in autism. Lancet Neurology, 1(6), 352-358.
35. Vasudev, A., Macritchie, K., Watson, S., Geddes, J. R., & Young, A. H. (2008). Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews (1), CD005171. doi: 10.1002/14651858. CD005171.pub2.
36. Wagner, K. D., Kowatch, R. A., Emslie, G. J., Findling, R. L., Wilens, T. E., McCague, K., et al. (2006). A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. American Journal of Psychiatry, 163(7), 1179-1186. doi: 10.1176/appi.ajp.163.7.1179.
37. Yildiz, A., Vieta, E., Leucht, S., & Baldessarini, R. J. (2011). Efficacy of antimanic treatments: Meta-analysis of randomized, controlled trials. Neuropsychopharmacology, 36(2), 375-389. doi: 10.1038/npp.2010.192.